Document:

exv4w3

 

Exhibit 4.3

CLASS A STOCKHOLDERS’ REGISTRATION RIGHTS AGREEMENT

     THIS CLASS A STOCKHOLDERS’ REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of
September 22, 2006, by and among Emergent Biosolutions, Inc., a Delaware corporation (together with
any successor thereto, the “Company”) and the holders of the Company’s Class A Common Stock, $0.01
par value per share, listed on Exhibit A attached hereto (each, a “Stockholder” and
together, the “Stockholders”). The Company and each of the Stockholders are referred to herein as
a “Party” and collectively, as the “Parties”.

     WHEREAS, the Stockholders are the owners of issued and outstanding voting capital stock of the
Company as more fully set forth on Exhibit A attached hereto; and

     WHEREAS, the Company and each of the Stockholders desire to provide for certain arrangements
with respect to the registration of shares of capital stock of the Company.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this
Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties hereto agree as follows:

     1. Certain Definitions. Capitalized terms used in this Agreement and not otherwise
defined shall have the following respective meanings:

          “Agreement” shall mean this Class A Stockholders’ Registration Rights Agreement, as amended,
restated, supplemented or otherwise modified from time to time.

          “Commission” shall mean the United States Securities and Exchange Commission or any other
federal agency at the time administering the Securities Act and the Exchange Act.

          “Common Stock” shall mean the Company’s Class A Common Stock, $0.01 par value per share.

          “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar
successor federal statute, and the rules and regulations of the Commission thereunder, all as the
same shall be in effect at the time.

          “Holder” shall mean each Stockholder or other holder of Registrable Securities who was
assigned registration rights by a Stockholder hereunder, in accordance with Section 7 hereof.

          “Initial Public Offering” shall mean the first underwritten public offering of Common Stock
for the account of the Company and offered on a “firm commitment” basis pursuant to an offering
registered under the Securities Act with the Commission on Form S-1 or its then equivalent.

          “Majority Holders” has the meaning set forth in Section 2(a)(ii).

 

 

          “Other Registrable Securities” shall mean securities of the Company (other than the
Registrable Securities) that holders of securities of the Company are entitled, by contract with
the Company, to have included in a registration statement (other than a registration statement on
Form S-4 or Form S-8 promulgated under the Securities Act or any successor forms thereto) filed by
the Company with the Commission for a public offering and sale of securities by the Company.

          “Person” shall mean any individual, sole proprietorship, partnership, joint venture, trust,
unincorporated organization, association, corporation, limited liability company, institution,
public benefit corporation, other entity or government (whether federal, state, county, city,
municipal, local, foreign, or otherwise, including any instrumentality, division, agency, body or
department thereof).

          “Registrable Securities” shall mean (a) the shares of Common Stock issuable or issued to each
Stockholder, (b) any Common Stock issued or issuable upon conversion of any capital stock of the
Company acquired by the Stockholders after the date hereof and (c) any Common Stock issued as (or
issuable upon the conversion or exercise of any warrant, right or other security which is issued
as) a dividend, stock split or other distribution with respect to, or in exchange for or in
replacement of, the shares referenced in clause (a) and (b) above;
provided, however, that notwithstanding anything to the contrary contained herein,
“Registrable Securities” shall not at any time include any securities (i) registered and sold
pursuant to the Securities Act, (ii) sold pursuant to Rule 144 or (iii) which could then be sold in
their entirety pursuant to Rule 144 without limitation or restriction.

          “Registration Date” shall mean the date upon which the registration statement pursuant to
which the Company shall have initially registered shares of Common Stock under the Securities Act
for sale to the public shall have been declared effective.

          “Rule 144” shall mean Rule 144 promulgated under the Securities Act or any successor
regulation.

          “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar successor
federal statute, and the rules and regulations of the Commission thereunder, all as the same shall
be in effect at the time.

     2. Registrations.

          (a) Demand Registration.

          (i) At any time after the expiration of 90 days after the Registration Date, if the
Company receives from the Holders of Registrable Securities then outstanding, a written
request to file a registration statement for Registrable Securities under the Securities Act
(a “Demand Notice”) in accordance with this Section 2(a), for which the anticipated
aggregate offering price to the public is not less than $25,000,000, then the Company shall
use commercially reasonable efforts to effect, as soon as practicable, such a registration
statement. Upon receipt of a Demand Notice, the Company shall give written notice of such
proposed registration to all Holders and shall offer to include in

-2-

 

such proposed registration any Registrable Securities requested to be included in such
proposed registration by such Holders who respond in writing to the Company’s notice within
30 days after delivery of such notice (which response shall specify the number of
Registrable Securities proposed to be included in such registration). The Company shall use
commercially reasonable efforts, as soon as practicable, to effect such registration on an
appropriate form, including Form S-2 or S-3, if available, under the Securities Act of the
Registrable Securities which the Company has been so requested to register;
provided, however, that the Company shall not be obligated to effect any
registration under the Securities Act except in accordance with the following provisions:

          (A) The Company shall not be obligated to file more than one registration
statement initiated by the Holders of Registrable Securities pursuant to this
Section 2(a);

          (B) The Company shall not be obligated to file a registration statement during
the period following the Registration Date when any of the Holders is subject to any
restrictions on disposition of Registrable Securities pursuant to any agreement
described in Section 6(a); and

          (C) The Company shall not be obligated to file any registration statement
during any period in which any other registration statement (other than on Form S-4
or Form S-8 promulgated under the Securities Act or any successor forms thereto)
pursuant to which securities of the Company are to be or were sold has been filed
and not withdrawn or has been declared effective within the prior [90] days.

          (ii) If the Holders of a majority of the Registrable Securities requested to be
included in a registration pursuant to this Section 2(a) (the “Majority Holders”) so
elect, the offering of such Registrable Securities pursuant to such registration shall be in
the form of an underwritten offering. In the event of such election, the Majority Holders
shall select one or more nationally recognized firms of investment bankers reasonably
acceptable to the Company to act as the lead managing underwriter or underwriters in
connection with such offering and shall select any additional investment bankers and
managers to be used in connection with the offering, which shall also be reasonably
acceptable to the Company.

          (iii) With respect to any registration pursuant to this Section 2(a), the
Company may include in such registration any Common Stock for its own account or on the
account of others; provided, however, that if a managing underwriter, if
any, advises the Company that the inclusion of all Registrable Securities and Common Stock
requested to be included by the Company in such registration would interfere with the
successful marketing (including pricing) of all such securities, then the number of
Registrable Securities and Common Stock proposed to be included in such registration shall
be included in the following order:

          (A) first, the Registrable Securities and the Other Registrable
Securities shall be included, pro rata based upon the aggregate number of

-3-

 

Registrable Securities and Other Registrable Securities to be included at the
time of such registration; and

          (B) second, any other Common Stock requested to be included by the
Company for its own account or on the account of others.

          (iv) At any time before the registration statement covering Registrable Securities
becomes effective, the Majority Holders may request the Company to withdraw or not to file
the registration statement. In that event, if such request of withdrawal shall have been
caused by, or made in response to, a material adverse effect or change in the Company’s
financial condition, operations, business or prospects, such Holders of Registrable
Securities shall not be deemed to have used their demand registration rights under this
Section 2(a).

          (b) Piggyback Registration. If, at any time or times after (but not including) an
Initial Public Offering, the Company shall seek to register any shares of its Common Stock under
the Securities Act for sale to the public for its own account or on the account of others (except
with respect to registration statements on Form S-4, S-8 or another form not available for
registering the Registrable Securities for sale to the public), the Company will give written
notice thereof to all Holders. If within 15 business days after their receipt of such notice one
or more Holders request in writing the inclusion of some or all of the Registrable Securities owned
by them in such registration, the Company will use commercially reasonable efforts to effect the
registration under the Securities Act of such Registrable Securities. In the case of the
registration of shares of capital stock by the Company in connection with any underwritten public
offering, if the principal underwriter determines that the number of Registrable Securities to be
offered must be limited, the Company shall not be required to register Registrable Securities of
the Holders in excess of the amount, if any, of shares of the capital stock which the principal
underwriter of such underwritten offering shall reasonably and in good faith agree to include in
such offering in addition to any amount to be registered for the account of the Company.

     3. Further Obligations of the Company.

          (a) Whenever the Company is required hereunder to register any Registrable Securities, it
agrees that it shall also do the following:

               (i) Prepare and file, and use commercially reasonable efforts to cause to become effective,
with the Commission a registration statement and such amendments and supplements to said
registration statement and the prospectus used in connection therewith as may be necessary to keep
said registration statement effective until the Holder or Holders have completed the distribution
described in the registration statement relating thereto (but for no more than 180 days or such
lesser period until all such Registrable Securities are sold) and to comply with the provisions of
the Securities Act with respect to the sale of securities covered by said registration statement
for such period;

               (ii) Furnish to each selling Holder a draft copy of the registration statement and such copies
of each preliminary and final prospectus as such Holder may

-4-

 

reasonably request to facilitate the public offering of its Registrable Securities;

               (iii) Enter into and perform its obligations under any reasonable underwriting agreement
required by the proposed underwriter, if any, in such form and containing such terms as are
customary;

               (iv) Use its commercially reasonable efforts to register or qualify the securities covered by
said registration statement under the securities or “blue sky” laws of such jurisdictions as any
selling Holder may reasonably request provided the Company shall not be required to qualify to do
business or file a general consent to service of process in connection therewith;

               (v) Cause upon or immediately after the effectiveness of a registration all such Registrable
Securities to be listed on each securities exchange or quotation system on which the Common Stock
of the Company is then listed or quoted;

               (vi) notify each Holder of Registrable Securities covered by a registration statement, at any
time when a prospectus relating thereto is required to be delivered under the Securities Act, of
(A) the issuance of any stop order by the Commission in respect of such registration statement, or
(B) the happening of any event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not
misleading in the light of the circumstances then existing; and

               (vii) provide a transfer agent and registrar for all Registrable Securities registered
pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later
than the effective date of such registration.

          (b) With a view to making available to the Holders the benefits of Rule 144, the Company
agrees to:

               (i) make and keep public information available, as those terms are understood and defined in
Rule 144, at all times after the effective date of the Initial Public Offering;

               (ii) file with the Commission in a timely manner all reports and other documents required of
the Company under the Securities Act and the Exchange Act, if any; and

               (iii) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (A) a written statement by the Company that it has complied with the information and
reporting requirements of Rule 144(c) and (B) a copy of the most recent annual or quarterly report
of the Company and such other reports and documents so filed by the Company.

          (c) From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the outstanding Registrable Securities, enter into
any agreement with any holder or prospective holder of any securities of the Company that would
allow such holder or prospective holder to include such securities in any registration

-5-

 

statement filed under Section 2 hereof, unless under the terms of such agreement, such
holder or prospective holder may include such securities in any such registration only to the
extent that the inclusion of such securities will not reduce the amount of the Registrable
Securities of the Holders that are included.

     4. Payment of Expenses by; Cooperation by, and Obligations of, Prospective Sellers.

          (a) Notwithstanding any other provision in this Agreement to the contrary, the Company and
the Holders shall each pay one-half of all expenses of any registration effected pursuant to
Section 2(a) hereof and the Holders shall pay in full any incremental expenses of
including the Holders’ Registrable Securities in a Piggyback Registration pursuant to Section
2(b) hereof, including, without limitation, all legal and accounting fees, printing costs,
listing fees and miscellaneous expenses, but excluding underwriters’ commissions or discounts
attributable to the Registrable Securities being offered and sold by the Holders, which shall be
borne exclusively by the Holders.

          (b) Each prospective seller of Registrable Securities shall furnish to the Company in writing
such information as the Company may reasonably request from such seller in connection with any
registration statement with respect to such Registrable Securities.

          (c) The failure of any prospective seller of Registrable Securities to furnish any
information or documents in accordance with any provision contained in this Agreement shall not
affect the obligations of the Company under this Agreement to any remaining sellers who furnish
such information and documents unless, in the reasonable opinion of counsel to the Company and/or
the underwriters, such failure impairs or adversely affects the offering or the legality of the
registration statement or causes the request not to meet the requirements of Section 2 of
this Agreement.

          (d) Upon receipt of a notice (telephonic or written) from the Company or the underwriter of
the happening of an event which makes any statement made in a registration statement or related
prospectus covering Registrable Securities untrue or which requires the making of any changes in
such registration statement or prospectus so that they will not contain any untrue statement of
material fact or omit to state any material fact required to be stated therein or necessary to
make the statements therein in light of the circumstances under which they were made not
misleading, the Holders of Registrable Securities included in such registration statement shall
discontinue disposition of such Registrable Securities pursuant to such registration statement
until such Holders’ receipt of copies of the supplemented or amended prospectus or until advised
by the Company or the underwriters that dispositions may be resumed.

          (e) Each Holder of Registrable Securities included in any registration statement will effect
sales of such securities in accordance with the plan of distribution given to the Company.

          (f) At the end of any period during which the Company is obligated to keep any registration
statement current and effective as provided in this Agreement, the Holders of

-6-

 

Registrable Securities included in such registration statement shall discontinue sales of
shares pursuant to such registration statement, unless they receive notice from the Company of its
intention to continue effectiveness of such registration statement with respect to such shares
which remain unsold and such Holders shall notify the Company of the number of shares registered
which remain unsold promptly upon expiration of the period during which the Company is obligated
to maintain the effectiveness of the registration statement.

          (g) No Person may participate in any underwritten registration pursuant to this Agreement
unless such Person (i) agrees to sell such Person’s securities on the basis provided in any
underwriting arrangements made with respect to such registration and (ii) completes and executes
all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents
reasonably required by the terms of such underwriting arrangements.

     5. Indemnification; Contribution.

          (a) Incident to any registration of any Registrable Securities under the Securities Act
pursuant to this Agreement, the Company will indemnify and hold harmless each Holder who offers or
sells any such Registrable Securities in connection with such registration statement (including
its partners (including partners of partners and stockholders of any such partners), and
directors, officers, employees, representatives and agents of any of them, and each person who
controls any of them within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act), from and against any and all losses, claims, damages, reasonable expenses and
liabilities, joint or several (including any reasonable investigation, legal and other expenses
incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding
or any claim asserted, as the same are incurred), to which they, or any of them, may become
subject under the Securities Act, the Exchange Act or other federal or state statutory law or
regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities
arise out of or are based on (i) any untrue statement or alleged untrue statement of a material
fact contained in such registration statement (including any related preliminary or definitive
prospectus, or any amendment or supplement to such registration statement or prospectus) or (ii)
any omission or alleged omission to state in such document a material fact required to be stated
in it or necessary to make the statements in it not misleading; provided, however,
that the Company will not be liable to the extent that (1) such loss, claim, damage, expense or
liability arises from and is based on an untrue statement or omission or alleged untrue statement
or omission made in reliance on and in conformity with information furnished in writing to the
Company by or on behalf of such Holder in accordance with Section 4(b) of this Agreement
for use in such registration statement, or (2) in the case of a sale directly by such Holder
(including a sale of Registrable Securities through any underwriter retained by such Holder to
engage in a distribution solely on behalf of such Holder), such untrue statement or alleged untrue
statement or omission or alleged omission was contained in a preliminary prospectus and corrected
in a final or amended prospectus, and such Holder failed to deliver a copy of the final or amended
prospectus at or prior to the confirmation of the sale of the Registrable Securities to the Person
asserting any such loss, claim, damage or liability in any case where such delivery is required by
the Securities Act or any state securities laws. With respect to such untrue statement or
omission or alleged untrue statement or omission in the information furnished in writing to the
Company by or on behalf of such Holder in accordance with Section 4(b) of this Agreement
for use in such registration statement, such Holder, on a

-7-

 

several and not joint basis, will indemnify and hold harmless the Company (including its
directors, officers, employees, representatives and agents), each other Holder (including its
partners (including partners of partners and stockholders of such partners) and directors,
officers, employees, representatives and agents of any of them, and each person who controls any
of them within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act),
from and against any and all losses, claims, damages, reasonable expenses and liabilities, joint
or several (including any reasonable investigation, legal and other expenses incurred in
connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim
asserted, as the same are incurred), to which they, or any of them, may become subject under the
Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common
law or otherwise.

          (b) If the indemnification provided for in Section 5(a) above for any reason is held
by a court of competent jurisdiction to be unavailable to an indemnified party in respect of any
losses, claims, damages, expenses or liabilities referred to therein, then each indemnifying party
under this Section 5, in lieu of indemnifying such indemnified party thereunder, shall
contribute to the amount paid or payable by such indemnified party as a result of such losses,
claims, damages, expenses or liabilities (i) in such proportion as is appropriate to reflect the
relative benefits received by the Company and the other Holders from the offering of the
Registrable Securities or (ii) if the allocation provided by clause (i) above is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company and the other Holders
in connection with the statements or omissions which resulted in such losses, claims, damages,
expenses or liabilities, as well as any other relevant equitable considerations. The relative
benefits received by the Company and the Holders shall be deemed to be in the same respective
proportions that the net proceeds from the offering received by the Company and the Holders, in
each case as set forth in the table on the cover page of the applicable prospectus, bear to the
aggregate public offering price of the Registrable Securities. The relative fault of the Company
and the Holders shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by or on behalf of the Company or the Holders and
the Parties’ relative intent, knowledge and access to information.

          The Company and the Holders agree that it would not be just and equitable if contribution
pursuant to this Section 5(b) were determined by pro rata or per capita allocation or by
any other method of allocation which does not take account of the equitable considerations referred
to in the immediately preceding paragraph. No person found guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from
any person who was not found guilty of such fraudulent misrepresentation.

          (c) The amount paid by an indemnifying party or payable to an indemnified party as a result of
the losses, claims, damages and liabilities referred to in this Section 5 shall be deemed
to include, subject to the limitations set forth above, any legal or other expenses reasonably
incurred by such indemnified party in connection with investigating or defending any such action or
claim, payable as the same are incurred. The indemnification and contribution provided for in this
Section 5 will remain in full force and effect regardless of any investigation made by or
on behalf of the indemnified parties or any officer, director, employee, agent or

-8-

 

controlling person of the indemnified parties. No indemnifying party, in the defense of any
such claim or litigation, shall enter into a consent of entry of any judgment or enter into a
settlement without the consent of the indemnified party, which consent will not be unreasonably
withheld. Any indemnified party that proposes to assert the right to be indemnified under this
Section 5 will, promptly after receipt of notice of commencement or threat of any claim or
action against such party in respect of which a claim is to be made against an indemnifying party
under this Section 5 notify the indemnifying party in writing (such written notice, an
“Indemnification Notice”) of the commencement or threat of such action, enclosing a copy of all
papers served or notices received (if applicable), but the omission so to notify the indemnifying
party will not relieve the indemnifying party from any liability that the indemnifying party may
have to any indemnified party under the foregoing provisions of this Section 5 unless, and
only to the extent that, such omission results in the forfeiture of substantive rights or defenses
by the indemnifying party. The indemnified party will have the right to retain its own counsel in
any such action if (i) the employment of counsel by the indemnified party has been authorized by
the indemnifying party, (ii) the indemnified party’s counsel, with the concurrence of indemnifying
party’s counsel, shall have reasonably concluded that there is a substantial likelihood of a
conflict of interest between the indemnifying party and the indemnified party in the conduct of the
defense of such action or (iii) the indemnifying party shall not in fact have employed counsel to
assume the defense of such action within a reasonable period of time following its receipt of the
Indemnification Notice, in each of which cases the fees and expenses of the indemnified party’s
separate counsel shall be at the expense of the indemnifying party; provided,
however, that the indemnified party shall agree to repay any expenses so advanced hereunder
if it is ultimately determined by a court of competent jurisdiction that the indemnified party to
whom such expenses are advanced is not entitled to be indemnified; and provided,
further, that so long as the indemnified party has reasonably concluded that no conflict of
interest exists, the indemnifying party may assume the defense of any action hereunder with counsel
reasonably satisfactory to the indemnified party.

          (d) In the event of an underwritten offering of Registrable Securities under this Agreement,
the Company and the Holders shall enter into standard indemnification and underwriting agreements
with the underwriter thereof. To the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the
underwritten public offering are in conflict with the provisions of this Section 5, the
provisions in the underwriting agreement shall control.

          (e) The obligation of the Company and Holders under this Section 5 shall survive the
completion of any offering of Registrable Securities in a registration statement under Section
2, and otherwise.

     6. Market Standoff Agreement.

          (a) In connection with the Initial Public Offering by the Company, each Holder, if requested
by the Company and the managing underwriter of the Company’s equity securities in such offering,
shall agree not to, directly or indirectly, offer, sell, pledge, contract to sell (including any
short sale), grant any option to purchase or otherwise dispose of any securities of the Company
held by it (except for any securities sold pursuant to such registration statement) for a period of
90 days (or such longer period, not to exceed 180 days, that the managing

-9-

 

underwriter specifies is required for successful completion of the Initial Public Offering)
following the effective date of such registration statement. Such agreement shall be in writing
and in form and substance reasonably satisfactory to the Holders, the Company and such underwriter
and pursuant to customary and prevailing terms and conditions. The foregoing provisions of this
Section 6(a) shall not apply to the sale of any shares to an underwriter pursuant to an
underwriting agreement, and shall only be applicable to the Holders if all officers and directors
and 5% or greater stockholders of the Company enter into similar or more restrictive agreements
with respect to any shares of common stock of the Company that are beneficially held by them and
that are not being sold by them in connection with the Company’s Initial Public Offering.

          (b) Each Holder agrees that in the event the Company proposes to offer for sale to the public
any of its equity securities after the Initial Public Offering, and if (i) such Holder holds
beneficially or of record 5% or more of the outstanding equity securities of the Company, (ii)
requested by the Company and the managing underwriter of Common Stock or other securities of the
Company, and (iii) all other such 5% stockholders are requested by the Company and such underwriter
to sign, and actually do sign, a similar or more restrictive agreement restricting the sale or
other transfer of shares of the Company, then such Holder will not directly or indirectly, offer,
sell, pledge, contract to sell (including any short sale), grant any option to purchase or
otherwise dispose of any securities of the Company held by it (except for any securities sold
pursuant to such registration statement), for a period of 90 days (or such longer period, not to
exceed 180 days, that the managing underwriter specifies is required for successful completion of
the offering) following the effective date of such registration statement. Such agreement shall be
in writing and in form and substance reasonably satisfactory to the Holders, the Company and such
underwriter and pursuant to customary and prevailing terms and conditions.

     7. Transferability of Registration Rights.

          (a) Subject to Section 7(b) below, the rights to cause the Company to register
Registrable Securities pursuant to Section 2(a) or Section 2(b) hereof may be
assigned (but only with all related obligations) by a Holder to a transferee of such Registrable
Securities that is an affiliate, partner, member, limited partner, retired partner, retired member,
or stockholder of a Holder; provided, however, that (x) the Company is, within a reasonable time
after such transfer, furnished with written notice of the name and address of such transferee and
the Registrable Securities with respect to which such registration rights are being transferred;
and (y) such transferee agrees in writing to be bound by and subject to the terms and conditions of
this Agreement. For the purposes of determining the number of shares of Registrable Securities
held by a transferee, the holdings of a transferee that is an affiliate, limited partner, retired
partner, member, retired member, or stockholder of a Holder shall be aggregated together and with
those of the transferring Holder.

          (b) Notwithstanding the foregoing, no Holder may, directly or indirectly, sell, assign,
transfer, pledge, bequeath, hypothecate, mortgage, grant any proxy with respect to, or in any way
encumber or otherwise dispose of any Registrable Securities, except in accordance with Article II
of the Class A Stockholders Agreement, dated June 30, 2004, among the Company and the Class A
Stockholders of the Company.

-10-

 

     8. Miscellaneous.

          (a) Notices. Except as otherwise expressly provided herein, all notices, requests,
demands, claims, and other communications hereunder will be in writing. Any such notice, request,
demand, claim, or other communication hereunder shall be deemed duly given (a) upon confirmation
of facsimile, (b) one business day following the date sent when sent by overnight delivery and (c)
five business days following the date mailed when mailed by registered or certified mail return
receipt requested and postage prepaid at the addresses specified on the signature pages hereto (or
such other address for a Party as shall be specified by such Party by like notice).

          (b) Entire Agreement. This Agreement, together with the instruments and other
documents hereby contemplated to be executed and delivered in connection herewith, contains the
entire agreement and understanding of the parties hereto, and supersedes any prior agreements or
understandings between or among them, with respect to the subject matter hereof.

          (c) Successors and Assigns. The parties intend that this Agreement shall not benefit
or create any right or cause of action in or on behalf of any person other than Parties hereto and
their respective successors and permitted assigns.

          (d) Amendments and Waivers. Except as otherwise expressly set forth in this
Agreement, any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or
prospectively), with the written consent of the Company and the Holders of at least a majority of
the Registrable Securities. All Parties hereby acknowledge and agree that significant
modifications may be made to this Agreement without the consent of each of the Holders due to the
operation of this Section 8(d) which does not require the consent of each Holder for an
amendment hereto. No waivers of or exceptions to any term, condition or provision of this
Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or
continuing waiver of any such term, condition or provision.

          (e) Counterparts; Facsimile Execution. This Agreement may be executed in multiple
counterparts, each of which shall constitute an original but all of which shall constitute but one
and the same instrument. One or more counterparts of this Agreement may be delivered via
telecopier, with the intention that they shall have the same effect as an original counterpart
hereof. Facsimile execution and delivery of this Agreement is legal, valid and binding for all
purposes.

          (f) Captions. The captions of the sections, subsections and paragraphs of this
Agreement have been added for convenience only and shall not be deemed to be a part of this
Agreement.

          (g) Severability. Each provision of this Agreement shall be interpreted in such
manner as to validate and give effect thereto to the fullest lawful extent, but if any provision
of this Agreement is determined by a court of competent jurisdiction to be invalid or
unenforceable under applicable law, such provision shall be ineffective only to the extent so
determined and such invalidity or unenforceability shall not affect the remainder of such

-11-

 

provision or the remaining provisions of this Agreement; provided, however, that the Company
and a majority of Holders shall negotiate in good faith to attempt to implement an equitable
adjustment in the provisions of this Agreement with a view toward effecting the purposes of this
Agreement by replacing the provision that is invalid or unenforceable with a valid and enforceable
provision the economic effect of which comes as close as possible to that of the provision that
has been found to be invalid and unenforceable.

          (h) Governing Law. This Agreement and the rights and obligations of the Parties
hereunder shall be governed by, and construed in accordance with, the laws of the State of
Delaware.

          (i) Submission to Jurisdiction.

               (i) The Parties agree that any suit, action or proceeding with respect to any dispute,
controversies or claims or any judgment entered by any court in respect thereof may be brought in
any state or federal court in the State of Delaware and any appellate court thereof and irrevocably
and unconditionally submits to the non-exclusive jurisdiction of such courts for the purpose of any
such suit, action, proceeding or judgment. Each of the Parties hereto agrees that final judgment
in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by
suit on the judgment or in any other manner provided by law. Each of the Parties further submits,
for the purpose of any such suit, action, proceeding or judgment brought or rendered against it, to
the appropriate courts of the jurisdiction of its domicile.

               (ii) The Parties agree that any suit, action or proceeding with respect to the Agreement or
any judgment entered by any court in respect thereof may be brought in the competent courts of the
State of Delaware, and irrevocably submits to the non-exclusive jurisdiction of such courts for the
purpose of any such suit, action, proceeding or judgment.

               (iii) Nothing herein shall in any way be deemed to limit the ability of any Party to serve any
such process of summons, complaint and other legal process in any other manner permitted by
applicable law or to obtain jurisdiction over, or bring any suit, action or proceeding against, any
other Party in such other jurisdiction, and in such manner, as may be permitted by applicable law.

               (iv) The Parties also irrevocably consent, if for any reason any of the Party’s authorized
agent for service of process of summons, complaint and other legal process in any action, suit or
proceeding is not present in Delaware, to the service of such papers being made out of those courts
by mailing copies of the papers by registered United States air mail, postage prepaid, to the Party
at its address specified in Section 8(a). In such a case, the relevant Party shall also
send by facsimile, or have sent by facsimile, a copy of the papers to all Parties.

               (v) Service in the manner provided in Section 8(j) in any action, suit or proceeding
will be deemed personal service, will be accepted by each of the Parties as such and will be valid
and binding upon such Party for all purposes of any such action, suit or proceeding.

          (j) Appointment of Process Agent. The Parties hereby irrevocably appoint Corporation
Service Company (the “Process Agent”), with an office on the date hereof at 2711

-12-

 

Centerville Road, Wilmington, Delaware 19808, United States of America as its agent to
receive on behalf of each of the Parties service of copies of the summons and complaint and any
other process which may be served in any suit, action or proceeding. Each Party agrees that the
failure of the Process Agent to give any notice of any such service of process to such Party shall
not impair or affect the validity of such service or, to the extent permitted by applicable law,
the enforcement of any judgment based thereon. Such appointment shall be irrevocable as long as
any amounts payable under this Agreement or the terms and conditions of this Agreement are
outstanding, except that if for any reason the Process Agent appointed hereby ceases to be able to
act as such, each Party shall, by an instrument reasonably satisfactory to the other Parties,
appoint another Person in the State of Delaware as such Process Agent subject to the approval
(which approval shall not be unreasonably withheld) of the other Parties. Each of the Holders
covenants and agrees that it shall take any and all reasonable action, including the execution and
filing of any and all documents, that may be necessary to continue the designation of a Process
Agent pursuant to this Section 8(j) in full force and effect and to cause the Process
Agent to act as such.

          (k) Other Methods of Service. Nothing herein shall in any way be deemed to limit the
ability of any Party to serve any such process or summonses in any other manner permitted by
applicable law or to obtain jurisdiction over, or bring any suit, action or proceeding against,
the other Parties in such other jurisdictions, and in such manner, as may be permitted by
applicable law.

          (l) Waiver of Inconvenient Forum, Etc.. Each of the Parties hereby irrevocably
waives any objection that it may now or hereafter have to the laying of the venue of any suit,
action or proceeding arising out of or relating to this Agreement brought in any state or federal
court in the State of Delaware, United States of America, and hereby further irrevocably waives
any claim that any such suit, action or proceeding brought in any such court has been brought in
an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in
any such suit, action or proceeding shall be conclusive and may be enforced in any court to the
jurisdiction of which the Parties are or may be subject, by suit upon judgment.

          (m) Waiver of Jury Trial. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING
DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (i)
CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE
FOREGOING WAIVER AND (ii) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO
ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS
SECTION.

[Signature page follows]

-13-

 

{COMPANY SIGNATURE PAGE}

          IN WITNESS WHEREOF, the Parties hereto have caused this Class A Stockholders’ Registration
Rights Agreement to be duly executed as of the date first set forth above.

	 	 	 	 	 
	COMPANY:	 	EMERGENT BIOSOLUTIONS INC.
	 
	 	 	 	 
	 

	 	By
	 	/s/ Fuad El-Hibri
	 

	 	 	 	 
	 

	 	 	 	Name: Fuad El-Hibri

Title: Chief Executive Officer
	 
	 	 	 	 
	 	 	Address:
	 
	 	 	 	 
	 	 	EMERGENT BIOSOLUTIONS INC.
	 	 	300 Professional Drive, Suite 250
	 	 	Gaithersburg, Maryland 20879
	 	 	Attention: General Counsel
	 	 	Telephone No.: (301) 944-0107
	 	 	Facsimile No.: (301) 944-0173

[Signature Page to Registration Rights Agreement]

 

 

{STOCKHOLDER SIGNATURE PAGE}

          IN WITNESS WHEREOF, the Parties hereto have caused this Class A Stockholders’ Registration
Rights Agreement to be duly executed as of the date first set forth above.

	 	 	 	 	 
	 	INTERVAC, LLC

 	 
	 	By:  	/s/ Fuad El-Hibri
 	 
	 	 	Name:  	Fuad El-Hibri 	 
	 	 	Title:  	General Manager 	 
	 

Address for Notices:

Intervac, LLC

1684 East Gude Drive

Suite 301

Rockville, MD 20850

Attn: Fuad El-Hibri

 

 

{STOCKHOLDER SIGNATURE PAGE}

          IN WITNESS WHEREOF, the Parties hereto have caused this Class A Stockholders’ Registration
Rights Agreement to be duly executed as of the date first set forth above.

	 	 	 	 	 
	 	BIOPHARM, LLC

 	 
	 	By:  	/s/ Robert G. Kramer
 	 
	 	 	Name:  	Robert G. Kramer 	 
	 	 	Title:  	General Manager 	 
	 

Address for Notices:

BioPharm, LLC

3500 N. Martin Luther King, Jr. Blvd.

Building One, 3rd Floor

Lansing, MI 48906

Attn: Robert G. Kramer

 

 

{STOCKHOLDER SIGNATURE PAGE}

          IN WITNESS WHEREOF, the Parties hereto have caused this Class A Stockholders’ Registration
Rights Agreement to be duly executed as of the date first set forth above.

	 	 	 	 	 
	 	MICHIGAN BIOLOGICS PRODUCTS, INC.	 
	 	 	 
	 	By:  	                                  /s/ Robert C. Myers
 	 
	 	 	Name:  	Robert C. Myers 	 
	 	 	Title:  	President 	 
	 

Address for Notices:

Michigan Biologics Products, Inc.

3500 N. Martin Luther King, Jr. Blvd.

Building One, 3rd Floor

Lansing, MI 48906

Attn: Robert C. Myers

 

 

{STOCKHOLDER SIGNATURE PAGE}

          IN WITNESS WHEREOF, the Parties hereto have caused this Class A Stockholders’ Registration
Rights Agreement to be duly executed as of the date first set forth above.

	 	 	 	 	 
	 	BIOVAC, LLC

 	 
	 	By:  	/s/ Fuad El-Hibri
 	 
	 	 	Name:  	Fuad El-Hibri 	 
	 	 	Title:  	General Manager 	 
	 

Address for Notices:

BioVac, LLC

1684 East Gude Drive

Suite 301

Rockville, MD 20850

Attn: Fuad El-Hibri

 

 

{STOCKHOLDER SIGNATURE PAGE}

          IN WITNESS WHEREOF, the Parties hereto have caused this Class A Stockholders’ Registration
Rights Agreement to be duly executed as of the date first set forth above.

	 	 	 	 	 
	 	BIOLOGIKA, LLC

 	 
	 	By:  	/s/ Mauro Gibellini
 	 
	 	 	Name:  	Mauro Gibellini 	 
	 	 	Title:  	General Manager 	 
	 

Address for Notices:

Biologika, LLC

3500 N. Martin Luther King, Jr. Blvd.

Building One, 3rd Floor

Lansing, MI 48906

Attn: Mauro Gibellini

 

 

{STOCKHOLDER SIGNATURE PAGE}

          IN WITNESS WHEREOF, the Parties hereto have caused this Class A Stockholders’ Registration
Rights Agreement to be duly executed as of the date first set forth above.

	 	 	 	 	 
	 	INTERVAC MANAGEMENT, LLC

 	 
	 	By:  	/s/ Fuad El-Hibri
 	 
	 	 	Name:  	Fuad El-Hibri 	 
	 	 	Title:  	General Manager 	 
	 

Address for Notices:

Intervac Management, LLC

1684 East Gude Drive

Suite 301

Rockville, MD 20850

Attn: Fuad El-Hibri

 

 

{STOCKHOLDER SIGNATURE PAGE}

          IN WITNESS WHEREOF, the Parties hereto have caused this Class A Stockholders’ Registration
Rights Agreement to be duly executed as of the date first set forth above.

	 	 	 	 	 
	 	ARPI, LLC

 	 
	 	By:  	/s/ Janice Mugriditchian
 	 
	 	 	Name:  	Janice Mugriditchian 	 
	 	 	Title:  	General Manager 	 
	 

Address for Notices:

ARPI, LLC

12001 Glen Road

Potomac, MD 20854

Attn: Janice Mugriditchian

 

EXHIBIT A

CLASS A STOCKHOLDERS

	 	 	 	 	 	 	 
	 	 	Class A Shares	 	Number of Shares
	1.
	 	Intervac, LLC	 	 	2,890,000	 
	2.
	 	BioPharm, LLC	 	 	1,412,896	 
	3.
	 	Michigan Biologics Products, Inc.	 	 	672,500	 
	4.
	 	BioVac, LLC	 	 	555,822	 
	5.
	 	Biologika, LLC	 	 	477,941	 
	6.
	 	Intervac Management, LLC	 	 	250,000	 
	7.
	 	ARPI, LLC	 	 	228,791exv10w17

 

Exhibit 10.17

STANDARD EMPLOYMENT CONTRACT 

This statement sets out the Terms & Conditions of employment between Emergent Product Development
UK Ltd (formerly Emergent Europe Limited) of 540~545 Eskdale Road, Winnersh Triangle, Wokingham,
Berkshire RG41 5TU, UK.

And Steven N. Chatfield residing at 31 Kenwood Drive, Beckenham, Kent, England BR3 6QX (‘the
Employee’).

	1.	 	Position
	 
	1.1	 	President of Emergent Product Development UK Ltd. reporting to the Chief Executive Officer of
Emergent BioSolutions Inc., a Delaware corporation (EBSI) with its offices located at 300
Professional Drive, Gaithersburg, MD, USA, or to such other person as the Chief Executive
Officer of EBSI may from time to time appoint.
	 
	2.	 	Preconditions
	 
	2.1	 	Your employment with the Company is conditional on (a) your producing at least two references
to the Company which the Company considers satisfactory, which has been satisfied, and (b)
such documentation as the Company may require to establish your right to work lawfully in the
United Kingdom and (c) the company receiving a medical report from its Occupational Health
Advisers which the Company considers satisfactory. (Please complete the enclosed
pre-employment health questionnaire and return to the Occupational Health Department in the
pre-paid envelope provided, your answers will be treated as strictly confidential and you may
be required to attend a health interview/ examination) Should you fail to produce to the
Company the required documentation, or should the medical report not prove satisfactory to the
Company, then any offer of employment by the Company may be withdrawn and if already accepted,
the Company may terminate your employment without notice or a payment in lieu of notice (or on
statutory minimum notice if applicable).
	 
	3.	 	Responsibilities
	 
	3.1	 	Your normal responsibilities are set out in your written job description but you may be
required to perform other reasonable tasks from time to time. (The job description does not
have contractual force, but is intended as a guide to your main duties). You may be required
to carry out your duties for the benefit of associated companies of the Company, without
payment of additional remuneration.
	 
	3.2	 	You are required to devote the whole of your time, attention and ability to the Company (or
any associated companies for whom you are required to work) and to use your best endeavours to
promote, develop and expand the business of the Company and its interests generally. You agree
not to have any outside business or other interests which conflict or

1

September
21, 2006

 

	 	 	may conflict with the interests of the Company or any associated Company or which may
otherwise interfere with or impede your ability to carry out your responsibilities for the
Company, without specific written approval of the Company given in advance.

	3.3	 	You must not act in any way that may be harmful to the Company’s interests and/or damages the
reputation of the Company.
	 
	3.4	 	You are expected to comply with the Company’s policies and procedures (as issued and/or
amended from time to time), even though these do not form part of your contract of employment.
The policies and procedures are available electronically on the Company’s systems or from the
Administration Office. Failure to comply, may lead to disciplinary action. In the event of a
conflict between the terms of this contract and any Company policy, the terms of this contract
will apply
	 
	3.5	 	You shall not at any time, (including during any period spent on garden leave), make any
disparaging, untrue or misleading oral or written statements concerning the business and
affairs of the Company or any associated company.
	 
	4.	 	Duration
	 
	4.1	 	Your employment with the Company commenced as of June 24, 2005 in accordance with the letter
agreement between you and EBSI dated September 16, 2005. Your prior period of employment with
EBSI counts towards your period of continuous employment.
	 
	4.2	 	Subject to clause 19 below, the period of notice required by either party to terminate your
employment is six (6) months. Notice under this sub-clause must be given in writing
	 
	4.3	 	Subject to any contrary provision of law, your employment will end automatically without the
need for notice of termination to be served, at the end of the month in which you reach the
age of 65, which is the Company’s normal retirement age.
	 
	5.	 	Salary
	 
	5.1	 	Your gross salary (“Salary”) will be One Hundred Forty Nine Thousand Nine Hundred Fourteen
Pounds (£149,914) per annum payable by equal monthly instalments directly to your bank or
building society account. It is our normal practice to pay Salary on approximately the 24th
day of each calendar month. Salary through December 31, 2005 has been paid through EBSI in
U.S. dollars. The above payment schedule for Salary will commence on January 1, 2006. Salary
will be accrued on a daily basis. The Company’s policy is to calculate daily pay on the basis
of a 260 working day year (or in a leap year a 261 working day year).
	 
	5.2	 	Salaries are generally reviewed annually each year in the Company’s discretion commencing in
2007. Any changes will be notified to you in writing.

2

September
21, 2006

 

	5.3	 	The Company reserves the right to deduct from your Salary or from any severance pay due to
you on the termination of your employment, any sums owing from you to the Company or any
associated company, including but not limited to loans, debts and sums paid to you by mistake
or through misrepresentation and you agree to the making of these deductions.
	 
	5.4	 	The Company shall make such Income Tax and National Insurance deductions from your
remuneration (including from any payments to which you may become entitled under Section 19
hereof) as shall be required by law
	 
	6.	 	Expenses
	 
	6.1	 	You will be reimbursed all out-of-pocket expenses necessarily and properly incurred by you on
the business of the Company or any associated company provided you produce to the Company such
evidence of actual payment of the expenses concerned as the Company reasonably requires.
	 
	7.	 	Hours of Work
	 
	7.1	 	Your normal hours of work are 09.00 — 17.00 (exclusive of lunch intervals and other breaks)
Monday to Friday inclusive, making a total of 35 hours per week. Times of attendance will be
agreed with your Manager. You will however be expected to work such extra hours as may be
reasonably required for the purpose of completing your tasks efficiently and on time. You
agree that the limits on average weekly working time set out in paragraph 4(1) of the Working
Time Regulations 1998 will not apply to you. However you may withdraw your consent on giving
the Company not less than 3 months’ prior written notice. Overtime is only paid in exceptional
circumstances and with the written agreement of your Line Manager.
	 
	8.	 	Mobility and Travel
	 
	8.1	 	While the Company’s offices in Winnersh, (wherever located there), will be your normal place
of work, the Company reserves the right to relocate its operations or open additional sites
elsewhere in the UK. If so requested by the Company on not less than one month’s notice, you
agree to move to a new place of work or the place of work of an associated company, within a
radius of 30 miles from Winnersh.
	 
	8.2	 	You will undertake any travel either in the UK or overseas as may be necessary to carry out
your responsibilities.
	 
	9.	 	Holiday
	 
	9.1	 	Our holiday year runs from 1st January to 31st December. In addition to the normal English
Public and Bank Holidays you are entitled to 25 days paid holiday in each holiday year, which
accrues at the rate of 25/52 days for each complete calendar week of

3

September 21, 2006

 

	 	 	employment. The Company reserves the right to require you to take up to 3 days of your
annual entitlement during the Christmas period.
	 
	9.2	 	Your holiday entitlement for the year in which you start or end your employment will be
calculated on a pro-rata basis.
	 
	9.3	 	Where you have not taken your full accrued holiday entitlement on leaving you will be paid in
lieu for your untaken entitlement calculated on a pro-rata basis up to the date of termination
of your employment. If you have taken more holiday than your accrued holiday entitlement for
that year, you agree that the Company is authorised to deduct the value of the excess days
from your Salary or from any severance pay due to you on the termination of your employment.
The Company reserves the right to require you to take any outstanding holiday leave during a
period of notice.
	 
	9.4	 	You are entitled to carry forward into the next holiday year a maximum of 5 days holiday
which have accrued but which have not been taken before the end of the holiday year. These 5
days must be taken by 31st March of the next holiday year. Any carried forward holiday
remaining at this date will lapse. You may not take more than 30 days holiday in any one year.
	 
	10.	 	Notification of Absence
	 
	10.1	 	If you cannot attend for work you should telephone the Company or arrange for someone to
telephone or otherwise deliver a message on your behalf as soon as possible on your first day
of absence and indicate when you expect to return to work. If your return to work is delayed
you should contact the Company again in the same way on each following day of absence.
	 
	10.2	 	If you are prevented by illness or accident from working for seven or more consecutive days
you must provide a medical practitioner’s statement on the eighth day and weekly thereafter. A
self-certification form must be completed and produced to the Company immediately following
your return to work for shorter periods of absence.
	 
	11.	 	Sick Pay
	 
	11.1	 	If you are entitled to Statutory Sick Pay (“SSP”) the Company will pay it to you.
	 
	11.2	 	During absence due to sickness or injury, Company Sick Pay equivalent to your normal Salary,
may be paid at the Company’s discretion. Statutory Sick Pay will be paid in accordance with
the then prevailing rules of the Statutory Sick Pay Scheme.
	 
	11.3	 	Full details of the Company Sickness/Absence Policy and Procedure are available
electronically on the Company’s systems and from the Administration Office.
	 
	11.4	 	The Company provides permanent health insurance cover. Full details of this cover (including
conditions of eligibility, the rules and benefits to which cover is subject) are

4

September 21, 2006

 

	 	 	available from the Administration Office. The Company reserves the right to arrange
equivalent cover through an alternative insurer.
	 
	12.	 	Pension Scheme
	 
	12.1	 	The Company agrees to contribute 10% of your Salary in equal monthly installments to an
appropriate and qualified personal pension plan nominated by you. This contribution is
conditional upon your making monthly contributions equal to 2.5% of your Salary to the said
plan. You agree that your contributions to the plan may be made by the Company making the
relevant deductions from your Salary and paying the required amount into the plan on your
behalf. The said contributions are subject to the rules of the plan as amended from time to
time and will be capped at Inland Revenue limits. No Contracting Out certificate is in force
in respect of employment with the Company.
	 
	13.	 	Bonus Scheme
	 
	13.1	 	You will be eligible to participate in any bonus scheme the Company establishes from time to
time (if at all), for employees of your level, subject to the rules of the scheme. For 2005
you shall be eligible for a bonus (hereinafter, the “Bonus”), which shall be capped at thirty
percent (30%) of the portion your salary earned by you during that year, inclusive any salary
paid by EBSI. Notwithstanding anything to the contrary contained herein, the determination as
to whether any Bonus shall be awarded, and the amount of the Bonus, if any, shall be made in
the sole and absolute discretion of the Board of Directors of the Company or EBSI, or such
other person or committees as may be delegated that responsibility. The Committee’s criteria
for awarding any Bonus shall be based on its assessment your job performance and the Company’s
financial performance during the applicable Period. The relative weight to be given to each
such factor shall also be within the Company’s sole and absolute discretion. The Company
reserves the right to amend, replace or withdraw any such bonus scheme from time to time.
Further details are available from the Administration Office. The fact that a bonus is paid in
one or more years is no guarantee that bonuses will be paid in subsequent years. As the bonus
is also intended to incentivise employees to remain in the employment of the Company, payment
of any bonus is conditional on your remaining in the employment of the Company and not being
under, or having given, notice to terminate your employment at the date bonus is payable.
	 
	14.	 	Life Assurance
	 
	14.1	 	You will become a member of the Company’s Life Assurance Scheme when you commence permanent
employment subject to meeting any conditions of eligibility and the rules of the Scheme from
time to time. (These may require you to pass a medical examination to the satisfaction of the
benefit providers as a condition of cover). In the event of death during your employment the
sum of four times Salary, subject to the Inland Revenue Earnings Cap from time to time, will
be payable.

5

September 21, 2006

 

	15.	 	Private Medical Cover
	 
	15.1	 	You may join the Company’s Private Medical Insurance Scheme at the Company’s expense and you
may pay for dependants (as defined in the scheme) to be included. The Company reserves the
right at any time to arrange equivalent cover through an alternative insurer. The provision of
cover (including alternative cover) is conditional on your satisfying any conditions (such as
passing a medical examination) and accepting any restriction imposed by the insurer. Details
of the scheme in operation are available from the Administration office.
	 
	16.	 	Medical Examination
	 
	16.1	 	The Company may reasonably require you to be examined by a Company appointed doctor at its
own expense. The doctor may report to the Company and its professional advisers, on your
fitness to do your job or other appropriate work. The Company may also require verification
from your own GP that you are fit to return to work after a period of absence or sickness
incapacity.
	 
	17.	 	Grievance and Disciplinary Procedures
	 
	17.1	 	The Company’s Grievance and Disciplinary procedures can be viewed electronically on the
Company’s systems and are also available from the Administration Office. It is the Company’s
policy to deal fairly with disciplinary issues and grievances, which arise, in accordance with
these procedures. The Grievance and Disciplinary Procedures do not form part of your contract
or otherwise have contractual effect As can be seen if you have a grievance relating to your
employment or wish to appeal against disciplinary action or decisions, you should, in the
first instance, notify your line manager in writing making it clear that you are raising it
formally. If the grievance is against your line manager personally, you should notify your
grievance or appeal in writing to a member of the Executive Committee.
	 
	18	 	Company Systems
	 
	18.1	 	The Company’s e-mail and Internet system must be used for Company and only essential personal
use in accordance with the Office Systems Policy which is available electronically on the
Company’s system and from the Administration office.
	 
	19	 	Termination
	 
	19.1	 	The Company can dismiss you without prior notice or pay in lieu (and you will not be entitled
to damages) for conduct amounting to gross misconduct or any other conduct or performance
issues of equivalent seriousness. A non-exhaustive list of the grounds for summary dismissal
is contained in the Company’s Disciplinary Procedure.
	 
	19.2	 	The Company reserves the right to pay you your base Salary in lieu of any unexpired period of
notice less income tax and employee NI contributions.

6

September 21, 2006

 

	19.3	 	Once notice of termination has been given by either party.

	 	(a)	 	the Company may send you on paid leave of absence, suspend you from performing
your job and/or exclude you from entering our premises (“garden leave”). During your
suspension you will continue to receive your Salary and contractual benefits. During
your employment or any notice period, the Company may, in its absolute discretion,
assign you to different tasks consistent with your position or require you to perform
no tasks at all. This may include requiring you to stay at home and to have no contact
with the Company’s clients, suppliers or employees for part or all of your suspension
period. You will continue to receive your Salary and all your contractual benefits
during the suspension period Your implied duties of loyalty and good faith will
continue to apply whether or not you are actually working and you may not be engaged or
employed by or take up any office or partnership in any other company, firm or
business, or trade on your own account without the Company’s written permission.
	 
	 	(b)	 	you must not make any public statements in relation to the Company or your
employment or its termination .

	19.4	 	At the end of your employment, or earlier if the Company requests, for whatever reason you
must return all Company property, including all equipment, documents, computer disks or tapes
and all other tangible items in your possession or control belonging to, or containing any
confidential information of, the Company or an associated employer.
	 
	19.5	 	In the event that as a result of incapacity you became eligible to receive benefits under the
Company’s permanent health insurance scheme, the Company may, in its discretion, a) continue
your employment only to the extent necessary and solely to ensure that you continue to be
treated as an employee for the purposes of the permanent health insurance scheme or b)
terminate your employment. During such time, you will not be entitled to any remuneration or
other benefit from the Company and the Company will have no obligation to continue your
employment or provide any work or payment to you, if you recover from the incapacity
	 
	19.6	 	(a) If during the term of this Agreement your employment with the Company is terminated by
the Company without Cause, other than under the circumstances described in Section 19.7(a)
below, then you shall become entitled to:

	 	(i)	 	any unpaid Base Salary and accrued holiday entitlement through
the date of termination;
	 
	 	(ii)	 	pro rata target annual bonus in respect of the year of
termination;
	 
	 	(iii)	 	any bonus earned but unpaid as of the date of termination for
any previously completed year;
	 
	 	(iv)	 	reimbursement for any unreimbursed expenses incurred by you
prior to the date of termination;
	 
	 	(v)	 	an amount equal to 75% of your Base Salary;

7

September 21, 2006

 

	 	(vi)	 	employee and fringe benefits and perquisites, if any, to which
you may be entitled as of the date of termination under the relevant plans,
policies and programs of the Company;
	 
	 	(vii)	 	continued eligibility for you and your eligible dependants
(where such dependents are then participants) to receive Employee Benefits (to
the extent permitted thereunder), for a period of 9 months following your date
of termination, except where the provision of such Employee Benefits would
result in a duplication of benefits provided by any subsequent employer; and
	 
	 	(viii)	 	any rights you may have under any Company stock option agreement held by you
that is outstanding on the date of termination of employment shall be governed
by the terms and conditions set forth in such stock option agreement.

	 	(b)	 	Any payments payable under this Section 19 shall be paid, in the Company’s sole and
absolute discretion, either as a single, lump sum payment within thirty days following the
termination of employment or payable in equal monthly installments over a term of 9 months.
	 
	 	(c)	 	If your employment with the Company is terminated by the Company with Cause (including
without limitation pursuant to Section 19.1, above), then you shall not be entitled to
receive any compensation, benefits or rights set forth in this Section 19.6 or in Sections
19.7 or 19.8 below (other than Salary and Employee Benefits including accrued but untaken
holidays, up to the date of termination of employment, less tax and any other deduction
required by law), and any stock options or other equity participation benefits vested on or
prior to the date of such termination, but not yet exercised, shall immediately terminate
and lapse. If circumstances arise which constitute Cause, but do not justify summary
termination of your employment by the Company under Section 19.1 or under English law, then
your employment under this Agreement may be terminated by the Company giving you the
statutory minimum period of notice required under English law, or a payment of Salary in
lieu thereof, net of tax, employee national insurance contributions and any other deductions
required by law.
	 
	 	(d)	 	If your employment with the Company is terminated by the Company pursuant under Section
19.1 or for Cause, you shall be obligated to comply with the obligations set forth in
subsections (i) through (iii), below. If your employment with the Company is terminated by
the Company, as a condition to payment of any of the amounts under Section 19.6(a), you
shall be obligated to comply with the obligations set forth in subsections (i) through (iv),
below:

	 	(i)	 	you shall not, for a period of nine (9) consecutive
months after the termination of your employment, less any period that you
are required to spend on “garden leave” in accordance with Section 19.3(a)
of this Agreement, directly or indirectly, either alone or in association
with others: (A) induce, counsel, advise, solicit or encourage, or attempt
to

8

September 21, 2006

 

	 	 	 	induce, counsel, advise, solicit or encourage any person employed or engaged
by the Company or any of its associated companies, who is carrying out the
functions of a director, associate director, vice-president, senior
vice-president, officer or other post that is higher in seniority than
persons with the job title of director, and with whom in each case you have
had dealings during the Relevant Period, to terminate his/her employment or
engagement with the Company, or any of its associated companies, or accept
employment with any other person or entity, (B) in connection with any
business which competes with the business of the Company or any of its
associated companies with which you are involved during the Relevant Period,
solicit, interfere with, or endeavor to cause any customer, client or
business partner of the Company or any of its associated companies, with
whom you have had business dealings on behalf of the Company or any of its
associated companies during the Relevant Period, to cease or reduce its
relationship with the Company, or any of its associated companies, or induce
or attempt to induce any such customer, or business partner to breach any
agreement that such customer, or business partner may have with the Company,
or any of its associated companies;
	 
	 	(ii)	 	you shall not, for a period of six (6) consecutive months after
the termination of your employment, less any period you are required to spend
on “garden leave” in accordance with Section 19.3(a) of this Agreement,
directly or indirectly, whether or not for compensation, and whether or not as
an employee, be employed or engaged or otherwise involved in any company, firm
or business, competing in the Territory with any part of the business of the
Company or of any of its associated companies with which you were involved
during the Relevant Period. The Territory shall mean England and any other
part of the UK and any other country, state, region or locality in which the
Company or such associated company is then doing business or marketing products
at the date on which your employment with the Company terminates, with which
business you were concerned or involved during the Relevant Period. Nothing in
this subsection shall prevent you from owning up to 3% of the issued shares or
securities of any publicly traded company. With respect to this sub-section,
but without prejudice to the generality of the foregoing, it is understood and
agreed that a business is not competing with the business of the Company or any
associated company if: (A) your duties with respect to such business relate
solely to discrete business units which do not compete with the business of the
Company or any associated company; or (B) the competitive activity is limited
to geographical markets or products in which the Company or any associated
company was not engaged (whether by manufacture, distribution, sale, or
development for manufacture, distribution, or sale) during the period of

9

September 21, 2006

 

	 	 	 	two (2) years immediately preceding the termination of your employment with
the Company.
	 
	 	(iii)	 	you shall, upon reasonable notice and at the Company’s
expense, cooperate fully with any reasonable request that may be made by the
Company (giving due consideration for your obligations with respect to any new
employment or business activity) in connection with any investigation,
litigation, or other similar activity to which the Company or any associated
company is or may be a party or otherwise involved and for which you may have
relevant information.
	 
	 	(iv)	 	you shall sign and deliver a waiver and release and/or, at the
Company’s option, a compromise agreement in a form acceptable to the Company
under which you shall release and discharge the Company and all associated
companies, officers, directors, employees, agents and affiliates, among others,
from and on account of any and all claims that relate to or arise out of the
employment relationship between the you and Company.

	 	(e)	 	Should you breach any obligation set forth in Section 19.6(d), above, (which breach
remains uncured for a period of 10 days following written notice) the Company shall be
relieved of any obligation to make further payments to you under this Section 19.6 and
	 
	 	(f)	 	Should you breach any obligation set forth in Section 19.6(d), above, (which breach
remains uncured for a period of 10 days following written notice) the Company shall be
entitled to receive full repayment and restitution of all amounts theretofore paid to you
under this Section 19.6.

	19.7	 	If during the term of this Agreement

	 	(a)	 	your employment with the Company is terminated by the Company without Cause, or your
resign for Good Reason, in each case within eighteen (18) months following a Change of
Control, or
	 
	 	(b)	 	your employment with the Company is terminated prior to a Change of Control (which
subsequently occurs) at the request of a party involved in such Change of Control, or
otherwise in connection with or in anticipation of a Change of Control,

	then in the case of each of clauses (a) and (b) you shall become entitled to the compensation,
benefits and rights set forth in Section 19.8 (a) through (g), inclusive.

	 
	19.8	 	In the event of a termination of your employment under the circumstances prescribed in Section
19.7 (a) or (b), you shall be entitled to:

10

September
21, 2006

 

	 	(a)	 	A cash lump sum, payable within thirty (30) days following the date of termination, of
employment equal to the sum of:

	 	(i)	 	your pro rata target annual bonus in respect of the year of
termination through the date of termination;
	 
	 	(ii)	 	any unpaid Base Salary and accrued holiday entitlement through
the date of termination;
	 
	 	(iii)	 	any bonus earned but unpaid as of the date of termination for
any previously completed year;
	 
	 	(iv)	 	reimbursement for any unreimbursed expenses incurred by you
prior to the date of termination;
	 
	 	(v)	 	an amount equal to 100% of your Compensation

	 	(b)	 	Such Employee Benefits, if any, to which you may be entitled as of the date of
termination of employment under the relevant plans, policies and programs of the Company.
	 
	 	(c)	 	Any unvested Company stock options held by you that are outstanding on the date of
termination of employment shall become fully vested as of such date, and the period during
which any Company stock option held by you that is outstanding on such date may be exercised
shall be extended to a date that is the later of the fifteenth day of the third month
following the date, or December 31 of the calendar year in which, such Company stock option
would otherwise have expired if the exercise period had not been extended, but not beyond
the final date such Company stock option could have been exercised if your employment had
not terminated, in each case based on the terms of such option at the original grant date.
	 
	 	(d)	 	Continued eligibility for you and your eligible dependents (where such dependents are
then participants) to receive Employee Benefits (to the extent permitted thereunder), for a
period of 12 months following the date of termination of your employment, except where the
provision of such Employee Benefits would result in a duplication of benefits provided by
any subsequent employer.
	 
	 	(e)	 	All rights you have to indemnification from the Company immediately prior to the Change
of Control shall be retained for the maximum period permitted by applicable law, and any
director’s and officer’s liability insurance covering you immediately prior to the Change of
Control shall be continued throughout the period of any applicable statute of limitations
and subject to the terms of the said insurance policy as amended from time to time.
	 
	 	(g)	 	The Company shall advance to you all costs and expenses, including all attorneys’ fees
and disbursements, incurred by you in connection with any legal proceedings (including
arbitration), which relate to the termination of employment or the interpretation or
enforcement of any provision of Section 19.7, and you shall have no

11

September 21, 2006

 

	 	 	 	obligation to reimburse the Company for any amounts advanced hereunder where you prevails in
such proceeding with respect to at least one material issue, it being acknowledged that
settlement of any such proceeding shall relieve you from any reimbursement obligation.

	19.9	 	Notwithstanding anything herein to the contrary, in the event that your employment is
terminated or you resign under circumstances that give rise to payment and/or benefits being made
or provided to you under Section 19.6 or Section 19.8 (the “Severance Payments”), you agree that
the Company may deduct the total amount of any and all “Notice Payments” paid or payable to you by
the Company from the total amount of the Severance Payments which would otherwise be due to you.
In this Agreement, “Notice Payments” shall mean: (a) all payments and/or benefits paid and/or
provided to you during any period of notice of termination of employment (whether notice is served
by you or by the Company); and (b) all payments in lieu of notice of termination of employment paid
to you by the Company. Any Severance Payments which are paid to you under this Agreement shall
offset, be credited towards and reduce the amount of any Notice Payments that may be due to you
under this Agreement or under English law.
	 
	19.10	 	The following terms as used in Sections 19.6 through 19.8 shall have the meanings set forth
below:

	 	 	 	“Applicable Bonus” shall mean the greater of the annual bonus that was paid to you in
respect of the most recently completed full calendar year or the maximum annual bonus that
could have been paid to you under an established bonus plan for such calendar year.
	 
	 	 	 	“Base Salary” shall mean your annual base salary in effect on the date of the Change of
Control or the date of termination, whichever is applicable.
	 
	 	 	 	“Cause” shall mean each of the following that results in demonstrable harm to the Company’s
financial condition or business reputation: (1) your conviction of or plea of guilty or no
contest to any felony, crime of moral turpitude or any crime under the laws of the United
Kingdom which is punishable by a term of imprisonment other than a driving offence; (2) your
dishonesty or disloyalty in performance of duties; (3) conduct by you that jeopardizes the
Company’s right or ability to operate its business; (4) your violation of any of the
Company’s policies or procedures, (including without limitation employee workplace policies,
anti-bribery policies, insider trading policy, communications policy, etc) if uncured within
two weeks of written notice by the Company; or (5) your willful malfeasance, misconduct, or
gross neglect of duty.
	 
	 	 	 	“Change of Control” shall have the meaning set forth in EBSI’s Severance Plan and
Termination Protection Program (“SPTPP”), as it may be amended from time to time. Any
terms defined in such definition shall have the meaning set forth in the SPTPP.
	 
	 	 	 	“Compensation” shall mean the sum of your Applicable Bonus and Base Salary.
	 
	 	 	 	 
	 
	                                                       
	 	 	 	September 21, 2006
	                                                        

12

 

	 	 	 	“Employee Benefits” shall mean the employee and fringe benefits and perquisites (including
without limitation all medical, dental, life insurance, disability and pension benefits)
made available to you (and your eligible dependents) immediately prior to a Change of
Control or a termination of employment, as the case may be, (or the economic equivalent
thereof where applicable laws prohibit or restrict such benefits).
	 
	 	 	 	“Good Reason” shall mean (i) a material decrease in your base salary or bonus opportunity,
(ii) a material diminution in the aggregate employee benefits and perquisites provided to
you, (iii) a material adverse change in your title, reporting relationship, duties or
responsibilities at the Company (it being agreed that any change in your title with EBSI
shall not qualify), or (iv) relocation of the primary office of the Company more than 60
kilometers from its current location.
	 
	 	 	 	“Relevant Period” shall means the period of 12 months prior to the termination of your
employment with the Company.

	20	 	Confidentiality/Inventions
	 
	20.1	 	You will, in fulfilling your responsibilities, have access to confidential information
relating to the Company or any associated employers and develop knowledge and influence over
the Company’s suppliers and/or customers and/or be involved in making inventions or creating
copyright material. You acknowledge that you have signed a separate Non-Disclosure and
Invention Assignment Agreement (“NDIAA”) in favor of EBSI the ultimate parent company of the
Company, which seeks to protect EBSI’s interests both during and after the termination of your
service in your capacity as Chief Scientific Officer of EBSI. Nothing in this Agreement shall
be construed to limit or alter your obligations under the NDIAA. Further, you agree that none
of your obligations under this Agreement shall limit or alter your obligations under the NDIAA
and that none of your obligations under the NDIAA shall limit or alter your obligations under
this Agreement. You further agree that you will not assert any differences with respect to
your obligations under this Agreement from those under the NDIAA as a defense to any
obligations under the NDIAA, or this Agreement, respectively.
	 
	20.2	 	You undertake that you not, save in the proper performance of your duties for the Company,
either during your employment or after its termination for whatever reason, use (whether for
your own benefit or for the benefit of any other person, firm, company, corporation or
organisation), divulge or communicate to any person firm, company, corporation or
organisation, except authorised members of the Company, any trade secrets or Confidential
Information of or relating to the Company, any associated company, the business of the Company
or any associated company, any customer of the Company or any associated company or any other
person, firm, company or organisation with whom or which the Company or any associated company
is involved in any kind of business dealings, joint venture or partnership, which in each case
has been disclosed to you by the Company, which may be created by you for the Company or which
may otherwise have come to your attention as a result of your employment with the Company.
	 
	 	 	 
	 
	                                                       
	 	 	September 21, 2006
	                                                        

13

 

	20.3	 	This restriction shall cease to apply to information or knowledge which comes into the public
domain, otherwise than by reason of your default, or which is required to be disclosed by law
or by a court or tribunal of competent jurisdiction. Nothing in this Agreement will prevent
you making a “protected disclosure” within the meaning of Section 43A-L Employment Rights Act
1996, provided that you have first followed and exhausted any reasonable Company procedure in
relation to the reporting of any alleged wrongdoing or malfeasance on the part of the Company
or any associated company or any of its/their officers, directors, employees or advisers.
	 
	20.4	 	‘Confidential Information’ shall, subject to clause 20.3 above, include, but shall not be
limited to, business and marketing plans, customer and price lists, the requirements of
customers and potential customers for products and services of the Company or any associated
company, management accounts, budgets and other sales or financial data, the terms on which
the Company or any associated Companies do business with customers or other third parties,
details of any pending or threatened litigation, details of confidential and proprietary
computer technology (including source and object codes and algorithms), any confidential
information relating to scientific data, formulae or processes, (including unpublished
research and development reports, details of products and services in the course of
development) and any other information which is the subject of an obligation of confidence
owed to a third party.
	 
	20.5	 	In the case of inventions employees must sign a separate claim to inventorship in a form
acceptable to the Company.
	 
	20.6	 	You agree that it is part of your normal duties at all times to consider in what manner
and by what new methods or devices the products, services, processes, equipment or systems of
the Company and each Group Company might be improved and to further the intellectual property
interests of the Company.
	 
	20.7	 	You will promptly and fully disclose to the Company full details of any Inventions and
any works embodying IPR, which you make or originate either by yourself or jointly with other
persons during the course of your employment whether or not during working hours or using
Company premises or resources and whether or not as a general or specific assignment, which
relate or are reasonably capable of being used in the business of the Company and/or any
associated company. You acknowledge that all IPR subsisting (or which may in the future
subsist) in all such works and Inventions shall automatically, on creation, vest in the
Company to the fullest extent permitted by law. To the extent that they do not vest in the
Company automatically, you hold them on trust for the Company. The obligations of this Clause
will apply both during and after your employment.
	 
	20.8	 	To the extent that any Inventions and any works embodying IPRs created by you prior to the
date of this Agreement are not otherwise vested in the Company, you hereby assign and transfer
them to the Company, its successors and assigns, with full title guarantee.
	 
	 	 	 
	 
	 	 	September 21, 2006

14

 

	20.9	 	For the avoidance of doubt, Clauses 20.7 and 20.8 shall not apply to any IPR or ownership of
Inventions listed in Exhibit A which relate to the subject matter of your employment by the
Company and which have been made or conceived by you, alone or jointly with others, prior to
your employment with the Company.
	 
	20.10	 	At any time during your employment or thereafter, (despite the termination of this
Agreement) and at the Company’s expense, you will do all such acts and things (including
execute such documents, take such actions and make such applications) as may be necessary (or
as the Company may reasonably request) in order to substantiate, confirm or vest effectually
any IPRs owned wholly or partially by the Company under English, Irish or foreign laws or
pursuant to this Agreement, and any other protection as to ownership or use of the same (in
any part of the world) in the Company, or as the Company may direct, (jointly if necessary
with any joint inventor or maker/author thereof). You hereby irrevocably appoint the Company
for these purposes to be your attorney in your name and on your behalf to execute and do such
acts and things and execute any such documents as set out above.
	 
	20.11	 	You agree that you will not at any time make use of or exploit the Company’s Inventions,
IPRs or other property for any purpose other than the proper performance of your duties or for
any purposes which has not been agreed by the Company in advance in writing by an authorised
person.
	 
	20.12	 	To the full extent permitted by applicable law, you irrevocably and unconditionally waive
all of your moral rights in relation to any Inventions and IPRs in all territories of the
world.
	 
	21	 	Statutory Particulars
	 
	21.1	 	This contract includes your statutory particulars of employment.
	 
	21.2	 	No collective agreements affect your terms and conditions of employment.

	22	 	Health & Safety
	 
	22.1	 	You have a legal duty to take reasonable care for the health and safety of yourself and of
other persons who may be affected by your acts or omissions at work. You must also cooperate
with the Company so that the Company can discharge its statutory obligations. No employee or
other person shall intentionally or recklessly interfere with, or misuse, anything that is
provided in the interests of health, safety or welfare.
	 
	23	 	Miscellaneous
	 
	23.1	 	Any notice to be given pursuant to these terms and conditions must be given in writing and
delivered either by courier, by hand, by first class post or by facsimile. Any notice to you
will be sent to your last known address or facsimile number or given to you at your place of
work and any notice to the Company should be sent to its registered office from

15

September 21, 2006

 

	 	 	time to time. A notice will be deemed to have been served at the time of delivery if sent by
courier or by hand, on completion of transmission by the sender if sent by facsimile and 2
clear days after the date of posting if sent by first class post.
	 
	24	 	Employee Data
	 
	24.1	 	You consent to the Company holding and processing both personal data and sensitive personal
data (the latter includes your religious beliefs, your ethnic or racial origin, information
relating to your physical or mental health and any unspent criminal convictions), for all
purposes relating to your employment. In particular you agree that the Company can hold and
process personal and sensitive personal data to: (a) pay and review your remuneration and
other benefits; (b) provide and administer any such benefits; (c) determine your fitness to
work for the Company or your entitlement to sick pay or maternity or other leave of absence;
(d) provide information to the Inland Revenue (or other taxation authorities), the police,
other regulatory bodies, the Company’s legal advisers and potential purchasers of the Company
or any business area in which you work and to any investors or potential investors in the
Company; (e) administer and maintain personnel records (including sickness and other absence
records); (f) carry out performance reviews, disciplinary or grievance procedures; (g) give
references to future employers; and (h) transfer personal and sensitive personal data
concerning you to a country outside the EEA (and, in particular, to the HR department of any
associated employer based overseas including in the US, particularly for the purposes of HR
administration) and you understand that such countries outside the EEA may not have laws to
protect your personal information.
	 
	25	 	Choice of Law
	 
	25.1	 	The terms and conditions of your employment are governed and will be construed in accordance
with English law and all claims, disputes and proceedings are subject to the exclusive
jurisdiction of the English courts
	 
	26	 	Definitions

	 	 	 	“associated company” or “associated employer” means any company which from time to time is a
subsidiary or a holding company of the Company or a subsidiary of such holding company and
“subsidiary” and “holding company” have the meanings attributed to them by section 736 of
the Companies Act 1985.
	 
	 	 	 	any Act or delegated legislation includes any statutory modification or re-enactment of it
or the provision referred to.
	 
	 	 	 	“Inventions” means any invention, idea, discovery, development, improvement or innovation,
whether or not patentable and whether or not recorded in any medium;
	 
	 	 	 	“IPRs” (Intellectual Property Rights) means patents, rights to Inventions, copyright and
related rights, trade marks, trade names and domain names, rights in get-up, rights in

16

September 21, 2006

 

	 	 	 	goodwill, rights in designs, rights in computer software, database rights, rights in
confidential information (including know-how and trade secrets) and any other intellectual
property rights, in each case whether registered or unregistered and including all
applications (or rights to apply) for, and renewals or extensions of, such rights and all
similar or equivalent rights or forms of protection which may now or in the future subsist
in any part of the world.

	27	 	Additional Provisions

	 	 	 	You acknowledge and agree that the Employment Agreement dated December 22, 2005 between you
and Emergent Europe Limited be and it hereby is terminated and superseded by this agreement.
	 
	 	 	 	You acknowledge and agree that the Employment Agreement dated January 3, 2005 between you
and EBSI be and it hereby is terminated and superseded by this agreement; provided however,
that the obligations, rights and agreements contained in Section 8 (Protection of the
Company), Section 9 (Inventions, Improvements and Copyrightable Materials) and Section 12
(Additional Obligations) shall survive and inure to the benefit of EBSI and the Company.
	 
	 	 	 	The letter agreement between you and EBSI dated September 16, 2005 shall be null and void
and the letter agreement between you and EBSI dated July 11, 2006 shall continue to apply as
it relates to the rights, obligations and agreements to serve as Chief Scientific Officer of
EBSI.
	 
	 	 	 	You acknowledge and agree that effective November 12, 2005 you resigned as Chief Executive
Officer of Emergent ImmunoSolutions Inc.

Please confirm that you accept this appointment on the above Terms and Conditions, by signing the
duplicate of this letter and returning it to me as soon as possible

IN WITNESS
WHEREOF this Deed has been executed and delivered as a deed on
September 22, 2006.

EXECUTED as a DEED

of the Company acting by:

	 	 	 	 	 
	By:

	 	/s/ Fuad El-Hibri	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Title:
	 	CEO	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Title:
	 	 	 	 
	 

	 	 	 	 

17

September 21, 2006

 

	 	 	 	 	 
	SIGNED as a DEED
	 	 	 	 
	by the Employee:
	 	/s/ S.N. Chatfield	 	 
	 

	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	In the presence of:-
	 	 	 	 
	 
	 	 	 	 
	Signature of Witness
	 	/s/ Carol Lindsay	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Name of Witness
	 	Carol Lindsay	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Address of Witness
	 	15 Winnersh. Gate	 	 
	 

	 	 	 	 
	 
	 	Wokingham RG41 5PL UK	 	 
	 	 	 
	 
	 	 	 	 
	Occupation
	 	Exec. PA	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Date: September 22, 2006	 	 

18

September 21, 2006

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]